Mark E. Jones, PhD

Basilea Pharmaceutica International Ltd., Allschwil, Switzerland, Switzerland

Poster(s):

• (1699) Safety and Outcomes of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis or Invasive Mucormycosis in Pediatric Patients
  Friday, October 13, 2023

  12:15 PM – 1:30 PM US ET

• (2162) In Vitro Antimicrobial Activity of Ceftobiprole against Streptococcus pneumoniae Isolates from the United States (2016–2020)
  Saturday, October 14, 2023

  12:15 PM – 1:30 PM US ET

• (2173) Activity of Ceftobiprole Against Enterococcus faecalis Clinical Isolates From the United States (2016–2020), Including Those From Difficult-to-Treat Infections
  Saturday, October 14, 2023

  12:15 PM – 1:30 PM US ET

• (2530) Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dose Selection for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Community-Acquired Bacterial Pneumonia (CABP)
  Saturday, October 14, 2023

  12:15 PM – 1:30 PM US ET

• (2531) Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dosing Regimens for Patients with Staphylococcus aureus Bacteremia (SAB)
  Saturday, October 14, 2023

  12:15 PM – 1:30 PM US ET

• (2532) Pharmacokinetic-Pharmacodynamic Analyses for Ceftobiprole Efficacy Based on Phase 3 Data from Patients with Staphylococcus aureus Bacteremia
  Saturday, October 14, 2023

  12:15 PM – 1:30 PM US ET

• (2561) Population Pharmacokinetic Analyses for Ceftobiprole Using Data from Phase 1 and 3 Studies
  Saturday, October 14, 2023

  12:15 PM – 1:30 PM US ET

• (2785) Characterization of Methicillin-resistant Staphylococcus aureus Bloodstream Isolates Recovered from Patients Enrolled in a Randomized, Double-blind, Multi-center Study to Establish the Efficacy and Safety of Ceftobiprole for Treatment of Bacteremia, Including Infective Endocarditis
  Saturday, October 14, 2023

  12:15 PM – 1:30 PM US ET